# SINGHE HOSPITALS PLC Financial Summary

Canonical URL: https://pal.lk/updates/sinh-financial-summary
Symbol: SINH.N0000
Company: SINGHE HOSPITALS PLC
Sector: Health Care Equipment & Services
Published: 2026-07-28T12:39:07Z
Last updated: 2026-07-28T12:39:07Z

# Singhe Hospitals PLC Financial Summary and Investment Analysis

## Executive Overview
Singhe Hospitals PLC operates a leading tertiary care private hospital in the Ratnapura district of Sri Lanka, supported by a rapidly expanding nationwide diagnostics network comprising 11 laboratories and over 60 sample collection centers. Over the reporting periods, the company has executed a highly successful financial and operational turnaround. Moving from a period of net losses in early 2023, the company has delivered consecutive quarters of robust profitability, driven by aggressive laboratory network expansion, digital transformation (including an ERP rollout and telemedicine launch), and disciplined cost management. The company exhibits strong revenue growth, expanding margins, and an improving balance sheet with decreasing reliance on debt. 

**Key periods covered:** Q2 2023 to Q2 2026 (Natural calendar quarters ending 2026-06-30).

## Financial Performance

## Revenue and Profitability Trends
The company has demonstrated an exceptional upward trajectory in revenue and profitability. Growth is primarily driven by higher patient volumes and the strategic expansion of its high-margin laboratory and diagnostic services, which now serve as the largest revenue contributors.

| Period | Revenue (Rs.) | Gross Profit (Rs.) | Net Profit/Loss (Rs.) | GP Margin (%) | NP Margin (%) |
|--------|---------|--------------|-----------------|-----------|--------------|
| Q1 2025 (Ended 2025-03-31) | 409,387,265 | 239,740,872 | 63,614,354 | 58.56% | 15.54% |
| Q2 2025 (Ended 2025-06-30) | 466,575,126 | 318,840,879 | 55,113,920 | 68.34% | 11.81% |
| Q3 2025 (Ended 2025-09-30) | 473,555,153 | 322,517,891 | 45,720,666 | 68.11% | 9.65% |
| Q4 2025 (Ended 2025-12-31) | 502,385,922 | 353,762,404 | 66,459,618 | 70.42% | 13.23% |
| Q1 2026 (Ended 2026-03-31) | 483,385,560 | 273,252,320 | 48,711,140 | 56.53% | 10.08% |
| Q2 2026 (Ended 2026-06-30) | 552,978,324 | 396,509,569 | 56,048,673 | 71.70% | 10.14% |

**Analysis:** 
*   **Revenue Growth:** For the 12 months ended Q1 2026, revenue hit Rs. 1.93 billion, marking an impressive 28% Year-over-Year (YoY) growth compared to the prior 12-month period (Rs. 1.51 billion). The latest quarter (Q2 2026) maintained this momentum with Rs. 552.9 million in revenue, a YoY increase of 18.5% compared to Q2 2025.
*   **Segment Drivers:** The laboratory segment is the standout performer, contributing 42% to total turnover (Rs. 811 million in the 12 months up to Q1 2026), outpacing inpatient hospital revenue.
*   **Margins:** Gross Profit margins have structurally improved, frequently exceeding 68% in recent quarters due to an optimized service mix, supply chain negotiations, and tech-driven operational efficiencies. 

## Balance Sheet Analysis
The company has significantly strengthened its financial position through consistent retained earnings and disciplined capital allocation.

| Period | Total Assets (Rs.) | Total Liabilities (Rs.) | Total Equity (Rs.) | Current Ratio (x) | Debt/Equity (%) |
|--------|----------------|----------------|----------------|----------|-----------|
| Q1 2025 (2025-03-31) | 1,495,461,018 | 582,997,277 | 912,463,741 | 1.15 | 19.4% |
| Q2 2025 (2025-06-30) | 1,551,545,459 | 583,967,797 | 967,577,662 | 1.36 | 16.5% |
| Q3 2025 (2025-09-30) | 1,629,487,365 | 616,189,039 | 1,013,298,326 | 1.78 | 19.9% |
| Q4 2025 (2025-12-31) | 1,703,047,147 | 623,289,204 | 1,079,757,943 | 1.82 | 17.0% |
| Q1 2026 (2026-03-31) | 1,810,726,545 | 662,711,389 | 1,148,015,156 | 1.64 | 14.7% |
| Q2 2026 (2026-06-30) | 1,858,352,065 | 654,288,236 | 1,204,063,828 | 1.84 | 12.7% |

**Analysis:**
*   **Assets:** Total assets grew to Rs. 1.86 billion by Q2 2026, driven by investments in modern medical equipment, digital infrastructure, and facility upgrades.
*   **Solvency:** Financial risk has sharply decreased. The interest-bearing debt-to-equity ratio improved from 19.4% in Q1 2025 to 12.7% by Q2 2026. 
*   **Liquidity:** The current ratio strengthened to a very healthy 1.84x by Q2 2026, indicating strong short-term liquidity, backed by rising cash reserves and efficient receivables collection.

## Cash Flow Analysis
| Period (Quarterly) | Net Cash from Operations (Rs.) | Net Cash from Investing (Rs.) | Net Cash from Financing (Rs.) | Cash & Equivalents End (Rs.) |
|--------|----------------|----------------|----------------|----------------|
| Q1 2025 (3 Months) | 67,021,350 | (49,581,760) | 486,782 | 44,813,509 |
| Q2 2025 (3 Months) | 76,048,337 | (53,656,406) | (19,092,989) | 53,169,529 |
| Q3 2025 (3 Months) | 28,809,993 | (17,225,305) | (26,999,985) | 35,237,739 |
| Q4 2025 (3 Months) | 177,721,863 | (148,301,873) | 3,087,439 | 82,378,017 |
| Q1 2026 (3 Months) | 258,515,359 | (281,686,834) | 38,460,690 | 65,159,803 |
| Q2 2026 (3 Months) | 66,102,105 | (32,673,225) | (26,771,347) | 71,817,336 |

**Analysis:** 
The company consistently generates positive operating cash flow, which is aggressively reinvested into Capital Expenditures (CAPEX) for laboratory networks, digital platforms, and medical equipment. Despite heavy capital deployment, the company has managed to maintain growing cash reserves without heavily relying on new debt facilities.

## Key Financial Ratios and Growth Indicators
*(Calculated as of the 12 months ending Q1 2026 unless noted)*
*   **Profitability:** 
    *   Return on Equity (ROE): 18.8%
    *   Return on Assets (ROA): 13.1%
    *   Return on Capital Employed (ROCE): 22.4%
*   **Valuation & Shareholder Metrics:**
    *   Earnings Per Share (EPS): Rs. 0.50 (for the 12 months ended Q1 2026), up from Rs. 0.27 previously. Q2 2026 generated Rs. 0.13 per share.
    *   Net Assets Per Share (NAPS): Increased to Rs. 2.79 by Q2 2026, up from Rs. 1.15 in 2022.
*   **Growth & Operational Indicators:** 
    *   Turnover CAGR (2022 to 2026): ~17.8%
    *   Digital Integration: Successful implementation of a comprehensive ERP system (March 2024) and launch of a Telemedicine Platform (December 2024).

## Economic and Market Context
The Sri Lankan healthcare sector operates in a highly regulated and economically sensitive environment. The company navigated severe macroeconomic pressures, inflation, and currency fluctuations that impacted the costs of imported medical consumables and equipment. Furthermore, the migration of skilled healthcare professionals (brain drain) poses a persistent industry-wide threat. However, Singhe Hospitals countered these challenges through strategic cost-efficiency measures, renegotiating supplier terms, implementing dynamic pricing, and investing in employee welfare to boost retention. 

## Future Potential and Outlook
Management outlines an aggressive but sustainable growth strategy centered on capturing demand in underserved regions:
*   **Laboratory Expansion:** Ongoing enhancement of 11 existing labs and 60+ collection centers, notably relocating the Karapitiya lab for better visibility and targeting unpenetrated regional markets.
*   **Cosmetic & Aesthetic Center:** Targeted for launch in July 2025, providing a high-margin revenue stream focused on medical skincare and aesthetic treatments. 
*   **Digital Healthcare:** Increased reliance on cloud-based systems and AI tools for workflow automation, diagnostics, and patient data management to scale operations without proportional overhead increases.

## Risks and Challenges
*   **Human Capital Retention:** High migration rates of medical staff require constant investment in competitive remuneration and training.
*   **Supply Chain Vulnerabilities:** Heavy reliance on imported pharmaceuticals and equipment leaves the company exposed to foreign exchange risks and import restrictions. 
*   **Cybersecurity & IT Resilience:** Heightened reliance on digital systems escalates the risk of data breaches and operational downtime.
*   *Mitigations:* The company actively utilizes long-term supplier contracts, aggressive cybersecurity frameworks, and performance-based staff incentives to hedge these risks.

## Shareholder and Corporate Information
*   **Major Shareholders:** Mr. A.M. Weerasinghe holds a commanding 86.41% stake (372,697,415 shares) in the company. 
*   **Public Holding:** The public float is highly constrained at just 13.25%, with 1,871 shareholders. 
*   **Stock Price Trend:** The market has rewarded the operational turnaround. The stock price surged from Rs. 2.80 in Q1 2024 to Rs. 19.20 by Q1 2026, and further to Rs. 24.40 by Q2 2026. 
*   **Dividends:** The directors did not recommend an ordinary dividend for the financial year ended Q1 2026, opting instead to retain earnings for funding strategic expansion and retiring debt.

## Investment Decision Indicators
**Strengths:**
*   **Robust Turnaround:** Successfully transitioned from historical losses to sustained, high-margin profitability.
*   **High-Growth Lab Segment:** The diagnostics arm provides highly scalable, high-margin revenue with lower capital intensity compared to traditional hospital beds.
*   **De-leveraged Balance Sheet:** Excellent liquidity metrics and a conservative debt profile (12.7% debt-to-equity) offer downside protection.
*   **Technology Leadership:** First-mover advantages in regional private telemedicine and sophisticated ERP utilization.

**Weaknesses:**
*   **Illiquidity:** A ~13% public float heavily restricts trading volume, making large entries or exits difficult without impacting the share price.
*   **Geographic Concentration:** Core hospital operations are concentrated in the Ratnapura area, though the lab network acts as a regional hedge.

**Opportunities and Threats:**
*   *Opportunities:* Medical tourism, aesthetics/cosmetics expansion, and further consolidation of the fragmented diagnostics market in regional Sri Lanka.
*   *Threats:* Exchange rate volatility impacting consumable costs; persistent talent drain to overseas markets.

**Overall Assessment:** 
Based purely on the financial and operational data, Singhe Hospitals PLC presents strong fundamentals indicative of a **Buy/Hold** profile for growth-oriented investors. The massive improvement in ROE (18.8%), rapid revenue growth (28% YoY), and falling debt levels showcase management's effective execution. However, prospective investors must heavily weigh the liquidity risk posed by the 86.4% insider ownership and the stock's recent exponential price appreciation (from Rs. 2.80 to Rs. 24.40), which suggests much of the turnaround may already be priced into the current valuation.